| |
| | Risk of Diabetes for Individuals with Schizophrenia Treated |
 | | Schizophrenia is a complex illness, often presenting a variety of treatment challenges.1,2 Antipsychotic medications play a critical role in controlling acute psychotic symptoms, and in preventing relapse.3—5 Although the first generation (or typical) antipsychotics are generally effective in controlling positive symptoms of schizophrenia, they are less effective in treating negative and cognitive symptoms. |
 | | For patients younger than 40, each individual atypical group had a significantly increased risk of diabetes compared with the group of all typical antipsychotics; in the analysis of all ages combined, the risperidone group was the only atypical group which did not have a significantly increased risk of diabetes. |
 | | Patients (aged 18 to 64) initiating antipsychotic treatment with atypical or typical agents, between October 1, 1996, and December 31, 1998, and diagnosed with schizophrenia (at least one diagnosis in the inpatient setting or at least two diagnoses in the outpatient setting (ICD9 295.xx)32 were identified. |
| www.jrnlappliedresearch.com /articles/Vol3Iss3/Zhao.htm (2903 words) |
|